Begin Assessment Provider evaluation A licensed clinician reviews your profile and designs a personalized treatment plan
Henry Meds Henry Meds focuses heavily on telehealth-based weight management services
The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Yulan Egan Aug 21, 2024 6 min read Across the past two years, GLP-1 agonistsa class of drugs that treat type 2 diabetes (T2D) and obesityhave not only become a major source of industry discourse, but a household name
Although the sample size was small with only 48 total participants randomized across the two treatment conditions, the randomized, double-blinded, experimental design provides some compelling preliminary evidence that semaglutide might reduce alcohol craving and the amount of alcohol consumed on drinking days in people with alcohol use disorder not actively seeking treatment
Analysis of over 80,000 electronic health records found that patients prescribed semaglutide for obesity had a 50-56% lower risk of developing alcohol use disorder compared to those on other anti-obesity medications
The sheer mechanical demands placed on this joint make it vulnerable to multiple types of damage